Akèy › Kansè nan tete › Maryland › Columbia
Etid klinik pou Kansè nan tete nan Columbia, MD
15 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Columbia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Northwest Hospital Center, Randallstown · 9 mi lwen
- William E Kahlert Regional Cancer Center/Sinai Hospital, Westminster · 25 mi lwen
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Maryland Oncology Hematology, Laurel · 10 mi lwen
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Columbia
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Catonsville · 6 mi lwen
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Maryland Oncology Hematology P.A., Columbia
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Maryland Oncology Hematology, P.A., Columbia
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Northwest Hospital Center, Randallstown · 9 mi lwen
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Central Maryland Radiation Oncology in Howard County, Columbia
Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Northwest Hospital, Randallstown · 9 mi lwen
- William E. Kahlert Regional Cancer Center, Westminster · 25 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Maryland Oncology Hematology P.A., Columbia
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Central Maryland Radiation Oncology in Howard County, Columbia
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Ap rekriteFaz 2
- Maryland Oncology Hematology, Columbia
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- William E Kahlert Regional Cancer Center/Sinai Hospital, Westminster · 25 mi lwen
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
Ap rekrite
- Central Maryland Oncology Center, Columbia
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Maryland Oncology Hematology, PA, Columbia
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Columbia
- Kansè poumon7 etid
- Kansè Poumon ki pa ti selil6 etid
- Sipwa6 etid
- Kansè pwostat6 etid
- Obèsite5 etid
- Kansè Metastatik5 etid
- Kansè vejik5 etid
- Kansè kolorektal5 etid
- Melanom4 etid
- Kansè pankreyas4 etid
- Kansè kolon4 etid
- Kansè Endomèt3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.